Clinical Trial Update: HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating HPV-16 vaccination in combination with pembrolizumab and cisplatin for intermediate-risk HPV-16-associated head and n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• HPV-16 Vaccination
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dan Zandberg | Conditions: HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING